A study of seven rule-based algorithms for the interpretation of HIV-1 genotypic resistance data in Thailand

Journal of Virological Methods

Volumn 151, Issue 1, 2008, Pages 79-86

  Poonpiriya, Vongsakorn ^a   Sungkanuparph, Somnuek ^a   Leechanachai, Pranee ^b   Pasomsub, Ekawat ^a   Watitpun, Chotip ^a   Chunhakan, Sirichan ^a   Chantratita, Wasun ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

HIV 1; Interpretation algorithms; Low cost; Resistance; Subtypes

Indexed keywords

ABACAVIR; AMPRENAVIR; DELAVIRDINE; DIDANOSINE; INDINAVIR; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR;

ALGORITHM; ARTICLE; CONTROLLED STUDY; COST; FOOD AND DRUG ADMINISTRATION; GENETIC VARIABILITY; GENOTYPE; HEALTH CENTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; THAILAND; UNITED STATES;

ALGORITHMS; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; REVERSE TRANSCRIPTASE INHIBITORS; THAILAND;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 44649084936     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2008.03.017     Document Type: Article

References (32)

1. Ariyoshi K., Matsuda M., Miura Tateishi H.S., Yamada K., and Sugiura W. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. J. Acquir. Immune. Defic. Syndr. 33 (2003) 336-342
2. Betts B.J., and Shafer R.W. Algorithm specification interface for human immunodeficiency virus type 1 genotypic interpretation. J. Clin. Microbiol. 41 6 (2003) 2792-2794
3. Brenner B., Turner D., Oliveira M., Moisi D., Detorio M., Carobene M., Marlink R.G., Schapiro J., Roger M., and Wainberg M.A. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 17 (2003) F1-F5
4. Cohen C.J., Hunt S., Sension M., Farthing C., Conant M., Jacobson S., Nadler J., Verbiest W., Hertogs K., Ames M., Rinehart A.R., and Graham N.M. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 16 (2002) 579-588
5. De Luca A., Cingolani A., di Giambenedetto S., Trotta M.P., Baldini F., Rizzo M.G., Bertoli A., Liuzzi G., Narciso P., Murri R., Ammassari A., Perno C.F., and Antinori A. Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J. Infect. Dis. 187 (2003) 1934-1943
6. Grossman Z., Vardinon N., Chemtob D., Alkan M.L., Bentwich Z., Burke M., Gottesman G., Istomin V., Levi I., Maayan S., Shahar E., Schapiro J.M., and Israel Multi-Center Study Group. Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B. AIDS 15 (2001) 1453-1460
7. Haubrich R., and Demeter L.M. Clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations. J. Acquir. Immune Defic. Syndr. 26 (2001) S51-S59
8. Hirsch M.S., Brun-V́ezinet F., Clotet B., Conway B., Kuritzkes D.R., D'Auila R.T., Demeter L.M., Hammer S.M., Johnson V.A., Loveday C., Mellors J.W., Jacobsen D.M., and Richman D.D. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin. Infect. Dis. 37 (2003) 113-128
9. Kantor R., and Katzenstein D. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev. 5 (2003) 25-35
10. Kijak G., Rubio H., Pampuro A.E., Zala S.E., Cahn C., Galli P., Montaner R., and Salomon J.S. Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms. HIV Med. 4 (2003) 72-78
11. Kuritzkes D.R., Bassett R.L., Hazelwood J.D., Barrett H., Rhodes R.A., Young R.K., Johnson V.A., and Adult ACTG Protocol 306 370 Teams. Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens. J. Acquir. Immune. Defic. Syndr. 36 1 (2004) 600-603
12. Loveday C., Dunn D., Green H., Rinehart A.R., McKenna P., and On behalf of the ERA Steering Committee. A randomized controlled trial of phenotypic resistance testing in addition to genotypic esistance testing: the ERA trial. Antivir. Ther. 8 Suppl. 1 (2003) S188
13. Munoz M., Carmona R., Pérez-Alvarez L., Cilla G., Suarez M.D., Delgado E., Contreras G., Corral J., de Goicoetxea M.J., Medrano L., Lezaún M.J., and Nájera R. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country. Spain J. Clin. Virol. 33 3 (2005) 224-229 Epub 2005 Jan 12
14. Parkin N., Chappey C., Maroldo L., Bates M., Hellmann N.S., and Petropoulos C.J. Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information. J. Acquir Immune. Defic. Syndr. 31 (2002) 128-136
15. Peeters M., Toure-Kane C., and Nkengasong J.N. Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials. AIDS 17 (2003) 2547-2560
16. Pieniazek D., Rayfield M., Hu D.J., Nkengasong J., Wiktor S.Z., Downing R., Biryahwaho B., Mastro T., Tanuri A., Soriano V., Lal R., Dondero T., and HIV Variant Working Group. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. AIDS 14 (2000) 1489-1495
17. Revela J., Betts B.J., Brun-Vezinet F., van Damme A.M., Descamps D., van Laethem K., Smith K., Schapiro J.M., Winslow D.L., Reid C., and Shafer R.W. HIV-1 protease and reverse transcriptase mutation pattern responsible for discordance between genotypic resistance interpretation algorithms. J. Acquir. Immun. Defic. Syndr. 33 1 (2003) 8-14
18. Robertson D.L., Anderson J.P., Bradac J.A., Carr J.K., Foley B., Funkhouser R.K., Gao F., Hahn B.H., Kalish M.L., Kuiken C., Learn G.H., Leitner T., McCutchan F., Osmanov S., Peeters M., Pieniazek D., Salminen M., Sharp P.M., Wolinsky S., and Korber B. HIV-1 nomenclature proposal. Science 288 (2000) 55-56
19. Ross L., Boulmé R., Fisher R., Hernandez J., Florance A., Schimt J.C., and Williams V. A Direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by seven resistance algorithms. AIDS Res. Hum. Retroviruses 21 11 (2005) 933-939
20. Ross L., Boulmé R., Fusco G., Scarsella A., and Florance A. Comparison of HIV Type 1 protease inhibitor susceptibility results in viral samples analyzed by phenotypic drug resistance assays and by six resistance algorithms: an analysis of a subpopulation of the CHORUS cohort. AIDS Res. Hum. Retroviruses 21 8 (2005) 696-701
21. Sarmati L., Nicastri E., Montano M.A., Dori L., Buonomini A.R., d'Ettorre G., Gatti F., Parisi S.G., Vullo V., and Andreoni M. Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy. J. Med. Virol. 72 (2004) 511-516
22. Sen S., Tripathy S.P., and Paranjape R.S. Antiretroviral drug resistance testing. J. Postgrad. Med. 52 3 (2006) 187-193
23. Shafer R.W. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin. Microbiol. Rev. 15 (2002) 247-277
24. Snoeck J., Kantor R., Shafer R.W., Laethem K.V., Deforche K., Chavalho A.P., Wynhoven B., Soares M.A., Cane P., Clarke J., Pillay C., Sirivichayakul S., Ariyoshi K., Holguin A., Rudich H., Rodrigues R., Bouzas L.F., Grossman Z., Soriano V., Sugiura W., Phanuphak P., Morris L., Weber J., Pillay D., Tanuri A., Harrigan R.P., Camacho R., Schapiro J.M., Katzenstein D., and Vandamme A.M. Discordance between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob. Agents Chemother. 50 (2006) 694-701
25. Sturmer M., Doerr H.W., and Preiser W. Variety of interpretation systems for human immunodeficiency virus type 1 genotyping: confirmatory information or additional confusion. Curr. Drug Targets Infect. Disord. 3 (2003) 373-382
26. Sturmer M., Doerr H., Staszewski W., and Preiser S. Comparison of nine resistance interpretation systems for HIV-1 genotyping. Antivir. Ther. 8 (2003) 55-60
27. Sutthent R., Arworn D., Kaoriangudom S., Chokphaibulkit K., Chaisilwatana P., Wirachsilp P., Thiamchai V., Sirapraphasiri T., and Tanprasertsuk S. HIV-1 drug resistance in Thailand: before and after National Access to Antiretroviral Program. J. Clin. Virol. 34 4 (2005) 272-276 Epub 2005 Apr 15
28. Tatt I.D., Barlow K.L., Nicoll A., and Clewley J.P. The public health significance of HIV-1 subtypes. AIDS 15 Suppl 5 (2001) S59-S71
29. Van Laethem K., De Luca A., Antinori A., Cingolani A., Perno C.F., and van Damme A.M. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antivir. Ther. 7 (2002) 123-129
30. Vercauteren J., and van Damme A.M. Algorithms for the interpretation of HIV-1 genotypic drug resistance information. Antiviral Res. 71 2-3 (2006) 335-342 Epub 2006 May 30
31. Vergne L., Snoeck J., Aghokeng A., Maes B., Valea D., Delaporte E., van Damme A.M., Peeters M., and van Laethem K. Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients. FEMS Immunol. Med. Microbiol. 46 1 (2006) 53-62
32. Vergne L., Peeters M., Mpoudi-Ngole E., Bourgeois A., Liegeois F., Toure-Kane C., Mboup S., Mulanga-Kabeya C., Saman E., Jourdan J., Reynes J., and Delaporte E. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J. Clin. Microbiol. 38 (2000) 3919-3925